



# TRENCHANT

## TRENCHANT TECHNOLOGIES CAPITAL PORTFOLIO COMPANY GNQ INSILICO APPOINTS LEADING CLINICAL TRIAL DESIGN SPECIALIST DR. JEROME SCHENTAG AS COO

VANCOUVER, BC – August 27, 2024 – Trenchant Technologies Capital (CSE: AITT; OTCQB: AITTF; “**Trenchant**” or the “**Company**”), announces that its portfolio company, GNQ Insilico (“**GNQ**”), a health tech company that is leveraging AI and quantum computing to improve the efficacy, accuracy and efficiency of clinical trials, has appointed Dr. Jerome Schentag as its Chief Operating Officer.

- Dr. Jerome Schentag brings to GNQ’s executive team 40+ years of clinical trial expertise in infectious diseases, critical care, sepsis and metabolic syndrome. Specifically, Dr. Schentag has extensive experience working with CROs to develop novel products and therapies based on mathematical modeling, including neural net modelling of diseases and their progression.
- GNQ Insilico’s (“GNQ”) proprietary genomics-driven platform is leveraging Artificial Intelligence (AI) and Quantum Computing technologies to create “intelligent **digital twins**” of human patients that can mimic how a drug will interact with an individual patient's unique biology, down to the cellular level. This platform will be co-marketed to life sciences companies in collaboration with a leading Fortune 100 computing and data management company.
- GNQ Insilico is a portfolio company of Trenchant Technologies Capital, a public issuer bringing unique private equity investment opportunities to retail investors. After a series of successful exits in the biotech, healthcare, and industrial sectors, Trenchant Technologies Capital is currently focused on investing in expertly managed, financially sound early-stage companies that are leveraging artificial intelligence to disrupt nascent business models in the medical and biomedical sectors.

### About Dr. Jerome Schentag

Dr. Jerome Schentag is a professor, inventor and expert in the commercialization of pharmaceutical products and therapeutic treatments with 40+ years of US and global clinical trial expertise in infectious diseases, critical care, sepsis and metabolic syndrome. He is also Emeritus Professor of Pharmacy at the State University of NY (SUNY) and is the CEO of Synergy Therapeutics, an oncology biotech company, where he is contributing to the development of an immune-oncology platform.

Of particular relevance to GNQ Insilico, Dr. Schentag has extensive experience working with CROs to develop novel products and therapies based on mathematical modeling, including neural net modelling of diseases and their progression. He has advised numerous organizations in the design and management of clinical trials, specifically in drug delivery methods and technologies.

Dr. Schentag is the inventor of several medical products and devices which have either reached the commercialization stage or are currently undergoing clinical trials. He is the inventor of the SmartPill, a medical device for the diagnosis of GI tract disorders, which was FDA approved and marketed worldwide by MedTronic. Dr. Schentag is also the co-inventor of Brake™, an oral mimetic of Roux-en-Y Gastric Bypass surgery that has applications for the prevention and management of Type 2 diabetes and other metabolic disorders, and is currently in [Phase 2 clinical trials under AphaiaPharma](#).

As an expert in neural net mathematical modeling of disease progression, Dr. Schentag is also the co-inventor of the [FS-Index](#), a leading means for the composite measurement of metabolic disease. He is also the co-inventor of [Cholestosomes™](#), a new means of orally delivering insulin which would allow diabetes patients to bypass insulin injections.

Dr. Schentag has filed more than 10 patents for his work in the US and globally. He obtained his Pharm.D. degree at the Philadelphia College of Pharmacy & Science, followed by a postdoctoral fellowship in Clinical Pharmacokinetics at the State University of NY (SUNY), Buffalo, where he continues to serve as a fellow in the Center for Entrepreneurial Leadership. Read more about Dr. Jerome Schentag [here](#).

### **Announcement of Financing**

The Company also announces that, further to its News Release of August 6, 2024, it has completed its non-brokered private placement financing (the “**Offering**”), pursuant to which it has issued 200,000 units (each, a “**Unit**”) for gross proceeds of \$50,000. Each Unit consists of one common share (each, a “**Share**”) and one common share purchase warrant (each, a “**Warrant**”). Each Warrant entitles the holder thereof to acquire one Share (each, a “**Warrant Share**”) at a price of \$0.50 per Warrant Share for a period of two years following closing. Proceeds of the Offering will be used for general working capital purposes.

The securities issued in connection with the Offering, and the Shares that may be issuable on exercise of the warrants, are subject to a statutory hold period expiring four months and one day after closing of the Offering.

---

### **ABOUT GNQ INSILICO:**

GNQ Insilico is an AI-biotechnology company pioneering the development and application of next-generation artificial intelligence capabilities to accelerate therapeutic research, clinical development, and individualized patient care. For more information, visit [www.gnqinsilico.com](http://www.gnqinsilico.com).

### **ABOUT TRENCHANT TECHNOLOGIES CAPITAL (CSE: AITT; OTCQB: AITTF; FSE: A40CR2)**

Trenchant Technologies Capital (CSE: AITT) is an investment issuer focused primarily on seeking investment in companies introducing novel technologies, including Artificial Intelligence and Quantum Computing, to traditional business models that are due for disruption. Trenchant’s team undergoes a rigorous due diligence process to identify companies led by seasoned management teams that are strong candidates for acquisition or an initial public offering (IPO).

In May 2024, Trenchant Technologies Capital acquired a 20% ownership interest in GNQ Insilico from parent company My Next Health Inc. Further, Trenchant holds an option to acquire up to 40% of GNQ Insilico. Learn more [here](#).

**ON BEHALF OF THE BOARD TRENCHANT CAPITAL CORP.**

Per: *"Eric Boehnke"* Eric Boehnke, CEO

For further information, please contact:

Trenchant Technologies Capital Corp. Eric Boehnke, CEO  
Phone: (604) 307-4274

**Forward-Looking Statements**

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements, including but not limited to GNQ's ability to successfully complete all necessary trials and regulatory approval processes necessary to be in a position to commercialize any of its technologies, including but not limited to its proprietary genomics-driven platform are only predictions. Various assumptions were used in drawing the conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management of GNQ at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Trenchant Capital and GNQ are under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.